A5337: Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy

Study Location:

Washington

Topic:

HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02440789?term=a5337&rank=1

IRB#:

Pro00013249

Coordinator:

Anna Wimpelberg

Enrollment:

Open

Trial Period:

Ongoing

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because the number of CD4 cells goes down). Despite successful treatment with anti-HIV therapy, latent reservoirs (infected cells that are not actively producing HIV) remain in the blood and contribute to a process called immune system activation and inflammation in the body. This may contribute to HIV persisting in cells in the body even while taking medications to treat HIV.

  • HIV-infected men and woman, at least 18 years of age
  • Taking anti-HIV medications that have controlled the HIV viral load (“undetectable” levels) for 2 or more years.
    • Protease inhibitors and cobicistat are not allowed on this study.
  • CD4 cell count greater than or equal to 400 cells/mm3
  • No active hepatitis B or C infection, tuberculosis, or shingles
  • No vaccinations in the past 14 days.

Anna Wimpelberg 
202-797-3589
awimpelberg@whitman-walker.org

Categories

Location
Topic

Clinical Trials

A5288: MULTIOCTAVE, Management Using the Latest Technologies...

The study is being done to: test a strategy of using a resistance test to choose anti-HIV drugs. Resistance tests look at the...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

P1070, Dose-Finding and Pharmacogenetic Study of Efavirenz...

Efavirenz (EFV) is an anti-HIV medicine that is commonly used to treat HIV infection in adults and children older than 3 years...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

HPTN 078: Enhancing Recruitment, Linkage to Care and...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Read More